AmerisourceBergen Corp. (NYSE:ABC) insider Robert P. Mauch sold 1,000 shares of AmerisourceBergen stock in a transaction dated Wednesday, June 13th. The shares were sold at an average price of $90.00, for a total transaction of $90,000.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Shares of AmerisourceBergen traded up $2.69, reaching $93.35, during trading on Thursday, MarketBeat Ratings reports. The company’s stock had a trading volume of 144,494 shares, compared to its average volume of 1,804,513. The company has a debt-to-equity ratio of 1.38, a quick ratio of 0.48 and a current ratio of 0.94. The stock has a market capitalization of $19.18 billion, a P/E ratio of 15.84, a price-to-earnings-growth ratio of 1.33 and a beta of 1.02. AmerisourceBergen Corp. has a 1-year low of $71.90 and a 1-year high of $106.27.
AmerisourceBergen (NYSE:ABC) last announced its quarterly earnings data on Wednesday, May 2nd. The company reported $1.96 earnings per share for the quarter, beating analysts’ consensus estimates of $1.83 by $0.13. The firm had revenue of $41.03 billion during the quarter, compared to analysts’ expectations of $40.56 billion. AmerisourceBergen had a net margin of 0.57% and a return on equity of 51.04%. The business’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.77 earnings per share. research analysts forecast that AmerisourceBergen Corp. will post 6.48 EPS for the current fiscal year.
Hedge funds have recently made changes to their positions in the stock. Hikari Tsushin Inc. acquired a new position in shares of AmerisourceBergen in the fourth quarter valued at approximately $106,000. Delpha Capital Management LLC purchased a new position in AmerisourceBergen in the fourth quarter worth approximately $137,000. Bronfman E.L. Rothschild L.P. lifted its stake in AmerisourceBergen by 54.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 1,698 shares of the company’s stock worth $146,000 after acquiring an additional 601 shares during the last quarter. Sciencast Management LP purchased a new position in AmerisourceBergen in the fourth quarter worth approximately $217,000. Finally, Synovus Financial Corp purchased a new position in AmerisourceBergen in the first quarter worth approximately $202,000. Hedge funds and other institutional investors own 66.18% of the company’s stock.
A number of equities research analysts have weighed in on ABC shares. Argus lifted their price target on shares of AmerisourceBergen from $93.96 to $115.00 and gave the company a “buy” rating in a research report on Monday, March 5th. Cowen reiterated a “buy” rating and set a $108.00 price target on shares of AmerisourceBergen in a research report on Tuesday, February 27th. Bank of America started coverage on shares of AmerisourceBergen in a research report on Tuesday, February 27th. They set a “buy” rating and a $111.00 price target for the company. Barclays started coverage on shares of AmerisourceBergen in a research report on Thursday, March 8th. They set an “equal weight” rating and a $104.00 price target for the company. Finally, Zacks Investment Research cut shares of AmerisourceBergen from a “buy” rating to a “hold” rating in a research report on Tuesday, March 20th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $103.07.
AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers.
Receive News & Ratings for AmerisourceBergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen and related companies with MarketBeat.com's FREE daily email newsletter.